← Back to Search

Cannabinoid

Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain for Fibromyalgia

Phase < 1
Waitlist Available
Led By Deborah Yurgelun-Todd, Ph.D.
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

Study Summary

This trial looks at whether THC, CBD, or a placebo can help with chronic non-cancer pain.

Eligible Conditions
  • Fibromyalgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Brain
Secondary outcome measures
Pain
Other outcome measures
Neurocognitive performance

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on painActive Control1 Intervention
This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
Group II: Cannabidiol's (CBD) effects on painActive Control1 Intervention
This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
Group III: PlaceboPlacebo Group1 Intervention
This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,095 Previous Clinical Trials
1,775,510 Total Patients Enrolled
6 Trials studying Fibromyalgia
512 Patients Enrolled for Fibromyalgia
Deborah Yurgelun-Todd, Ph.D.Principal Investigator - University of Utah Brain Institute
University of Utah
1 Previous Clinical Trials
68 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which members of the population are qualified to participate in this investigation?

"Eligibility for this trial necessitates that applicants suffer from chronic pain, be of adult age (18-50), and uniformly experience symptoms. Altogether, 75 participants are sought after."

Answered by AI

How many participants can potentially join this clinical trial?

"Indeed, as evidenced by the information on clinicaltrials.gov, this medical study is currently in pursuit of participants. It was initially published on February 1st 2018 and has undergone its most recent update on March 8th 2022. Furthermore, it requires 75 patients to be recruited from a single site."

Answered by AI

Are there any other reports that examine the potential of CBD to help with pain symptoms?

"Currently, 104 medical studies are being conducted to analyze the effects of Cannabidiol (CBD) on pain management. Nineteen trials have already entered Phase 3 and Belmont, Massachusetts is a major hub for this research with 331 worldwide locations running related tests."

Answered by AI

Is this research currently recruiting participants?

"Evidenced by recent edits on clinicaltrials.gov, this study is actively seeking volunteers for participation. The trial was initially posted in February of 2018 and its information has been amended most recently in March of 2022."

Answered by AI

Is there an upper limit for eligibility in this trial?

"Eligibility for this trial requires that the patient's age falls between 18 and 50 years old."

Answered by AI

What disorders and symptoms are typically alleviated through Cannabidiol (CBD) therapy?

"CBD is typically prescribed as a supplemental treatment for those who do not respond to standard therapies. In addition, it has been used to manage symptoms associated with multiple sclerosis, pharmacotherapy and pain-related symptoms."

Answered by AI
~10 spots leftby Apr 2025